ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
2.260
-0.140 (-5.83%)
At close: Nov 3, 2025, 4:00 PM EST
2.270
+0.010 (0.44%)
Pre-market: Nov 4, 2025, 5:56 AM EST
ImmunityBio Revenue
ImmunityBio had revenue of $26.43M in the quarter ending June 30, 2025, with 2,423.88% growth. This brings the company's revenue in the last twelve months to $56.60M, up 4,227.22% year-over-year. In the year 2024, ImmunityBio had annual revenue of $14.75M with 2,270.58% growth.
Revenue (ttm)
$56.60M
Revenue Growth
+4,227.22%
P/S Ratio
31.65
Revenue / Employee
$83,235
Employees
680
Market Cap
2.23B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 14.75M | 14.12M | 2,270.58% |
| Dec 31, 2023 | 622.00K | 382.00K | 159.17% |
| Dec 31, 2022 | 240.00K | -694.00K | -74.30% |
| Dec 31, 2021 | 934.00K | 329.00K | 54.38% |
| Dec 31, 2020 | 605.00K | -1.60M | -72.52% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 56.50B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.11B |
IBRX News
- 12 days ago - Looking For The Next Beyond Meat? Here Are The Top 10 Most Shorted Stocks - Benzinga
- 4 weeks ago - ImmunityBio: A Small Bet Is Warranted - Seeking Alpha
- 7 weeks ago - ImmunityBio: Still Too Early To Judge Anktiva, Although Clock Is Ticking - Seeking Alpha
- 2 months ago - ImmunityBio's ANKTIVA® Reverses Lymphopenia and Extends Overall Survival in Patients With Advanced Non-Small Cell Lung Cancer Resistant to Checkpoint Therapy - Business Wire
- 2 months ago - Initial Data Shows 100% Disease Control in 5 Out of 5 Patients With Recurrent Glioblastoma With Two Patients in Near Complete Response Treated With ImmunityBio's ANKTIVA®, NK Cell Therapy Plus Optune Gio® Device - Business Wire
- 2 months ago - ImmunityBio Announces Phase 2 Study of ANKTIVA® in Patients with Long COVID - Business Wire
- 2 months ago - ImmunityBio Reports Complete Responses in Non-Hodgkin Waldenstrom Lymphoma Patients with Chemotherapy-Free, First-In-Class CD19 CAR-NK Immunotherapy - Business Wire
- 3 months ago - ImmunityBio Announces Houston's Michael E. DeBakey VA Medical Center Is Among the First VA Hospitals to Administer ANKTIVA® to Bladder Cancer Patients - Business Wire